Compared with non-users, semaglutide 2.4 mg use was associated with a significantly lower risk of revised MACE-3 composite endpoint (heart attack, stroke, or all-cause death) by 57% (HR: 0.43; 95% ...

Semaglutide is the active ingredient in the weight loss medication Wegovy and the diabetes drugs Ozempic and Rybelsus, which ...

This occurred as the drug major Emcure Pharmaceuticals presented bioequivalence study report along with the Phase-III ...

As other pharmas drop next-gen obesity assets, Eli Lilly’s experimental oral GLP-1 has prompted weight loss up to ...

A real-world study found that semaglutide prescriptions were associated with improvements in weight, blood pressure, and ...

SAN ANTONIO — Semaglutide 2.4 mg (Wegovy) was associated with a 22% reduction in annual medical costs in people with overweight/obesity and heart failure, new research from Novo Nordisk found.

Three months into taking semaglutide, I found myself staring at a sandwich I’d made for lunch, feeling absolutely zero desire ...

Accepting the bioequivalence study report, the Subject Expert Committee (SEC) functional under the Central Drugs Standard ...

STEP UP trial showed 21% average weight loss with 7.2 mg Wegovy; one-third lost at least 25% of body weight. Semaglutide 7.2 mg safety was in line with the 2.4 mg dose, though slight risk increase ...

Semaglutide 7.2 mg achieved 20.7% weight loss at 72 weeks versus 17.5% for 2.4 mg and 2.4% for placebo in the STEP UP trial. 33.2% of participants on 7.2 mg lost ≥25% body weight compared to 16. ...

Semaglutide is marketed under the brand names Wegovy® (once-weekly semaglutide 2.4 mg injection), Ozempic® (once-weekly semaglutide 1.0 mg injection), and Rybelsus® (once-daily oral semaglutide ...